Smoldering plasma cell myeloma

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This study tests whether adding daratumumab to standard lenalidomide and dexamethasone can improve survival in people with high-risk smoldering myeloma, a condition that often progresses to active cancer. About 288 participants will receive either the standard two-drug regimen or…

This trial tests an experimental drug called CM-336 in people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The drug is a bispecific antibody designed to guide immune cells to destroy myeloma cells. Researchers want to see if it can ma…

This phase II trial compares the anti-cancer activity of teclistamab, an immunotherapy, against the standard combination of lenalidomide and dexamethasone in people with high-risk smoldering multiple myeloma. Smoldering myeloma is a pre-cancerous condition that often progresses t…

This Phase 2 trial is testing an investigational drug called linvoseltamab in 116 people with precancerous blood conditions that raise their risk of developing multiple myeloma. The goal is to see if the drug can eliminate abnormal plasma cells and lab signs of disease. Researche…

This study is for people with a high-risk form of smoldering multiple myeloma, an early stage of blood cancer. The purpose is to test a drug called belantamab mafodotin to find the safest dose and see if it can control the disease. About 30 participants will receive the drug, and…

This phase 2 trial tests iberdomide, an immunotherapy drug, alone or with dexamethasone in 68 people with intermediate- or high-risk smoldering multiple myeloma. The goal is to see if the treatment can shrink or control the cancer cells and delay progression to active myeloma. Pa…

This phase 2 trial tests whether combining teclistamab or talquetamab with daratumumab can delay the onset of multiple myeloma in 50 people with high-risk smoldering myeloma. The goal is to achieve no detectable cancer cells after 12 cycles of treatment. Researchers will also mon…

This study aims to detect multiple myeloma at its earliest stage, called MGUS, using a simple blood test. It will screen 1,665 Black adults and close relatives of people with plasma cell disorders. The goal is to reduce delayed diagnosis and improve outcomes by catching the disea…

This study tests whether a plant-based diet or supplements (omega-3 and curcumin) can change gut bacteria in people with MGUS or smoldering multiple myeloma, conditions that can lead to multiple myeloma. Researchers will measure butyrate levels in stool, a sign of healthy gut bac…

This study looks at whether a diet that includes longer overnight fasting and follows a Mediterranean eating pattern is practical for people with multiple myeloma or its early forms (MGUS or smoldering myeloma). About 120 adults will try this approach to see if they can stick wit…

This study looks at whether non-chemo approaches like physical activity, intermittent fasting, or adding a beta-blocker (propranolol) can improve immune function and quality of life in people with multiple myeloma or related blood disorders. Researchers will measure changes in im…

Researchers at Peking University First Hospital are building a prospective cohort of 2,000 people with plasma cell disorders, including multiple myeloma, amyloidosis, and related conditions. Participants give blood, bone marrow, and urine samples before and after treatment, and t…

This study is looking for 2,000 people who have a close family member with a blood cancer like multiple myeloma. The goal is to find early warning signs of the disease by collecting blood samples and health information over time. Participants will not receive any treatment, but t…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…

This observational study follows 200 people with early blood conditions (MGUS or smoldering myeloma) that sometimes turn into multiple myeloma. Researchers will track age, blood protein levels, bone marrow cells, genes, and bone health to find patterns that predict progression. N…

This study looks at people with early blood disorders (MGUS and smoldering myeloma) who are at risk of developing multiple myeloma, a type of bone marrow cancer. Researchers will use advanced genetic and immune testing on blood and bone marrow samples, along with mouth bacteria a…

This study looks at the quality of life of people with two early blood conditions: MGUS and smoldering myeloma. Researchers will ask 400 participants to fill out short questionnaires about their symptoms and concerns. The goal is to learn what matters most to patients, not to tes…

This study is creating a network of hospitals in Italy to find and treat AL amyloidosis earlier. Researchers will screen people with certain blood conditions (MGUS or smoldering myeloma) using special tests. The goal is to speed up diagnosis, connect patients to the right care, a…

This study is for 1,000 adults with early blood conditions called MGUS or smoldering multiple myeloma. Researchers want to find out why some people's conditions stay stable while others progress to active multiple myeloma. Participants will provide samples and have regular check-…

This study looks at whether eating a high-fiber, plant-based diet for 12 weeks can change the gut bacteria in people with smoldering multiple myeloma (SMM), a condition that can sometimes turn into active myeloma. Researchers will measure short-chain fatty acids (SCFAs) in stool …

This study follows 100 people with high-risk smoldering myeloma, a condition that may turn into active cancer. Researchers use advanced MRI scans and regular check-ups to track how the disease changes over two years. The goal is to better understand who progresses and how to impr…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…

This study collects and stores blood and tissue samples from 6,000 people with multiple myeloma and related conditions like smoldering myeloma and MGUS. The goal is to create a shared resource for researchers worldwide to study these diseases and improve patient care. Participant…

This study creates a registry for adults with plasma cell disorders, such as multiple myeloma and amyloidosis. Researchers will collect health information and optional blood samples to better understand these conditions. The goal is to gather data that could support future resear…

This study looks at how a short-term plant-based diet or supplements (omega-3, curcumin, or probiotics) change levels of butyrate—a healthy gut compound—in people with smoldering multiple myeloma or MGUS. About 200 participants will be randomly assigned to one of the diet or supp…

This study is creating a large collection of blood samples, tissue, and health information from 2,500 people with plasma cell disorders like multiple myeloma. Researchers will use this repository to better understand how the disease develops and changes over time. No new treatmen…